QIU Yuchong, LI Meizi, ZHANG Lu, LI Jian. A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia[J]. Journal of Rare Diseases, 2025, 4(1): 106-111. DOI: 10.12376/j.issn.2097-0501.2025.01.014
Citation: QIU Yuchong, LI Meizi, ZHANG Lu, LI Jian. A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia[J]. Journal of Rare Diseases, 2025, 4(1): 106-111. DOI: 10.12376/j.issn.2097-0501.2025.01.014

A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia

  • Hairy cell leukemia(HCL) is a rare malignant hematological tumor. This article presents the diagnosis and treatment of a patient with recurrent HCL. This patient, a 51-year-old female, was diagnosed with HCL in June 2013 and subsequently received monotherapy with cladribine. Post-treatment evaluation indicated a partial remission. In November 2023, she experienced chest tightness and shortness of breath with ultrasound revealing a right-sided pleural effusion. A follow-up examination in February 2024 confirmed the relapse of HCL. She was then treated with a combination of vemurafenib and rituximab, which resulted in a rapid complete remission without minimal residual disease. This case provides valuable insights into the management of recurrent HCL.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return